Prime Medicine downgraded by Citigroup with a new price target
$PRME
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Citigroup downgraded Prime Medicine from Buy to Neutral and set a new price target of $1.50
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 5/27/2025 | $1.50 | Buy → Neutral | Citigroup |
| 5/20/2025 | Overweight → Neutral | Analyst | |
| 5/20/2025 | Buy → Neutral | H.C. Wainwright | |
| 12/10/2024 | $10.00 | Mkt Outperform | JMP Securities |
| 5/20/2024 | $10.00 | Buy | H.C. Wainwright |
| 5/16/2024 | $10.00 | Neutral → Buy | Citigroup |
| 4/22/2024 | $17.00 | Buy | Chardan Capital Markets |
| 4/8/2024 | Buy | TD Cowen |
4 - Prime Medicine, Inc. (0001894562) (Issuer)
4 - Prime Medicine, Inc. (0001894562) (Issuer)
4 - Prime Medicine, Inc. (0001894562) (Issuer)
4 - Prime Medicine, Inc. (0001894562) (Issuer)
4 - Prime Medicine, Inc. (0001894562) (Issuer)
4 - Prime Medicine, Inc. (0001894562) (Issuer)
SCHEDULE 13G/A - Prime Medicine, Inc. (0001894562) (Subject)
S-3ASR - Prime Medicine, Inc. (0001894562) (Filer)
10-Q - Prime Medicine, Inc. (0001894562) (Filer)
CAMBRIDGE, Mass., Dec. 07, 2025 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (NASDAQ:PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced the publication of Phase 1/2 clinical data with PM359, the Company's investigational autologous hematopoietic stem cell product for p47phox chronic granulomatous disease (CGD) in the New England Journal of Medicine (NEJM). The data will also be presented in a poster session at the 67th American Society of Hematology (ASH) Annual Meeting, December 6-9, 2025 in Orlando, Florida. The publication, titled "Prime Editing for p47-phox Chronic Granulomatous Disease," reports initia
CAMBRIDGE, Mass., Nov. 25, 2025 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (NASDAQ:PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced that Allan Reine, M.D., Chief Executive Officer of Prime Medicine, will participate in a fireside chat at the 8th Annual Evercore Healthcare Conference on Tuesday, December 2, 2025, at 11:15 a.m. ET in Coral Gables, FL. A live audio webcast of the fireside chat will be available under "Events & Presentations" in the News & Events section of the Company's website at www.primemedicine.com. A replay of the webcast will be available on the Prime Medicine website for 90 days fol
CAMBRIDGE, Mass., Nov. 11, 2025 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (NASDAQ:PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced that Allan Reine, M.D., Chief Executive Officer of Prime Medicine, will participate in a fireside chat at the Jefferies Global Healthcare Conference on Tuesday, November 18, 2025, at 12:00 noon GMT (7:00 a.m. ET) in London, United Kingdom. A live audio webcast of the fireside chat will be available under "Events & Presentations" in the News & Events section of the Company's website at www.primemedicine.com. A replay of the webcast will be available on the Prime Medicine web
Citigroup downgraded Prime Medicine from Buy to Neutral and set a new price target of $1.50
Analyst downgraded Prime Medicine from Overweight to Neutral
H.C. Wainwright downgraded Prime Medicine from Buy to Neutral
-- Presented new preclinical research across multiple programs, including proof-of-concept data from in vivo rodent and large animal studies, as well as updates on proprietary delivery systems -- -- Shared detailed safety evaluation of lead Prime Editors across multiple programs; preliminary off-target analyses did not identify off-target editing, supporting potential best-in-class safety profile -- -- Received U.S. FDA Rare Pediatric Drug designation for PM359 for CGD; initiated IND-enabling studies and remain on track to file IND application in 2024 -- -- Further extended intellectual property portfolio; U.S. PTO issued Prime Medicine's third patent, No. 11,795,452 --
-- Presented new preclinical data demonstrating ability of Prime Editing to correct causative mutation of CGD and highlighting ability of PASSIGE™ platform to multiplex edit CAR-T cells at ASGCT Annual Meeting -- -- Entered strategic collaboration with Cimeio Therapeutics; multiplexing Cimeio's shielded variants with therapeutic edits may meaningfully expand reach of Prime Editing -- -- Cash, cash equivalents, investments and restricted cash balance of $221.1 million as of June 30, 2023 -- CAMBRIDGE, Mass., Aug. 07, 2023 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (NASDAQ:PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapie
-- New preclinical data for PM577 in Wilson's Disease (WD) to be presented at AASLD; on-track to file IND and/or CTA in H1'26, with initial clinical data expected in 2027 -- -- Nominated PM647 as development candidate for Alpha-1 Antitrypsin Deficiency (AATD); on-track to file IND and/or CTA in mid-2026, with initial clinical data expected in 2027 -- -- Strengthened leadership team with the appointment of Matthew Hawryluk, Ph.D., M.B.A. as Chief Business Officer -- -- Company to host virtual KOL event at 8:00am ET on Wednesday, November 12, 2025 to showcase Wilson's Disease Strategy -- CAMBRIDGE, Mass., Nov. 07, 2025 (GLOBE NEWSWIRE) -- In a release issued earlier today by Pr
-- New preclinical data for PM577 in Wilson's Disease (WD) to be presented at AASLD; on-track to file IND and/or CTA in H1'26, with initial clinical data expected in 2027 -- -- Nominated PM647 as development candidate for Alpha-1 Antitrypsin Deficiency (AATD); on-track to file IND and/or CTA in mid-2026, with initial clinical data expected in 2027 -- -- Strengthened leadership team with the appointment of Matthew Hawryluk, Ph.D., M.B.A. as Chief Business Officer -- -- Company to host virtual KOL event at 8:00am ET on Wednesday, November 12, 2025 to showcase Wilson's Disease Strategy -- CAMBRIDGE, Mass., Nov. 07, 2025 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (NASDAQ:PRME), a biotechno
CAMBRIDGE, Mass., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (NASDAQ:PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced the appointment of Matthew Hawryluk, Ph.D., M.B.A. as Chief Business Officer (CBO). Dr. Hawryluk will lead Prime's corporate and business development initiatives, corporate strategy, and alliance management functions, advancing the company's efforts to expand the reach of Prime Editing through strategic partnerships and collaborations. "We are thrilled to welcome Matt to our leadership team," said Allan Reine, M.D., Chief Executive Officer of Prime Medicine. "Business devel
SC 13D/A - Prime Medicine, Inc. (0001894562) (Subject)
SC 13G/A - Prime Medicine, Inc. (0001894562) (Subject)
SC 13G - Prime Medicine, Inc. (0001894562) (Subject)